Table 1.

Studies reporting on the efficacy of immunotherapy in RET (rearranged during transfection)-positive patients

First author and year	Immune checkpoint inhibition	No. of patientsa	Partial response	Stable disease	Progressive disease	Median progression-free survival	Median overall survival
Offin et al. (2019) [9]	Anti-PD-(L)1 ± anti-CTLA-4	13	0	5	8	3.4b	NR
Mazieres et al. (2019) [10]	Anti-PD-(L)1	16	1	3	12	2.1	21.3
Guisier et al. (2020) [11]	Anti-PD-1	8	3	2	3	7.6	NR
Present report	Anti-PD-1	2	0	0	2	–	–

CTLA-4 Cytotoxic T lymphocyte antigen-4, NR not reported, PD-1 programmed cell death-1, PD-L1 programmed cell death ligand-1

^aEvaluable for response

^bOn 16 patients